Regulus Therapeutics
RGLS
$1.38
Share price
0.73%
Change (1 day)
-7.38%
Change (1 year)
Categories
Regulus Therapeutics (RGLS) - Net assets
Net assets on the balance sheet as of June 2023 : $33.99 M
According to Regulus Therapeutics's latest financial reports the company has $33.99 M in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Regulus Therapeutics - Net assets on balance sheet (from 2011 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2022-12-31 | $33.29 M | -39.42% |
| 2021-12-31 | $54.95 M | 111.17% |
| 2020-12-31 | $26.02 M | 30.03% |
| 2019-12-31 | $20.01 M | -441.9% |
| 2018-12-31 | $-5.86 M | -116.62% |
| 2017-12-31 | $35.21 M | -37.2% |
| 2016-12-31 | $56.07 M | -54.81% |
| 2015-12-31 | $0.12 B | -6.01% |
| 2014-12-31 | $0.13 B | 41.26% |
| 2013-12-31 | $93.45 M | 50.51% |
| 2012-12-31 | $62.09 M | -249.64% |
| 2011-12-31 | $-41.5 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $79.27 B | 233,094.11% | 🇫🇷 France |
 Biogen BIIB | $14.46 B | 42,434.64% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $32.03 B | 94,114.20% | 🇺🇸 USA |
 AstraZeneca AZN | $37.41 B | 109,956.77% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $15.33 B | 45,016.04% | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | $0.23 B | 587.24% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -$0.41 B | -1,300.49% | 🇺🇸 USA |